Synapse - Miguel-Angel Perales

Results (941)

Successful incorporation of electronic patient reported outcomes using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy

Meeting Abstract

Shah, G. L.; Lobaugh, S.; Sukhu, R.; Devlin, S. M.; Atkinson, T.; Kemeny, E.; Stetson, P.; Perales, M. A.; Giralt, S. A.; Scordo, M.
Blood (2023)

Fulltext@MSK | Save

Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy

Meeting Abstract

Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
Blood (2023)

Fulltext@MSK | Save

Improved overall survival with axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma among the elderly: A subgroup analysis of ZUMA-7

Meeting Abstract

Kersten, M. J.; Farooq, U.; Rapoport, A. P.; Locke, F. L.; Leslie, L. A.; Ghobadi, A.; Miklos, D. B.; Jacobson, C. A.; Munoz, J. L.; Johnston, P. B.; more...
Blood (2023)

Fulltext@MSK | Save

Ibrutinib added to standard conditioning and as consolidation therapy following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-b-cell subtype diffuse large B-cell lymphoma (ABC-DLBCL): Primary analysis of the US intergroup double-blind randomized phase III study alliance A051301/BMT-CTN 1201

Meeting Abstract

Andreadis, C.; Bobek, O.; Hsi, E. D.; Fenske, T. S.; Geyer, S. M.; Stiff, P. J.; Hill, B. T.; Horwitz, M.; Khimani, F.; Little, R. F.; more...
Blood (2023)

Fulltext@MSK | Save

Patient-reported outcomes of BMT CTN 1703: A randomized phase III study for GVHD prophylaxis - A quality of life evaluation

Meeting Abstract

Holtan, S. G.; Martens, M. J.; Al Malki, M. M.; Efebera, Y.; Kitko, C. L.; Reshef, R.; Rezvani, A. R.; Shaffer, B. C.; Solh, M. M.; Yao, J. M.; more...
Blood (2023)

Fulltext@MSK | Save

Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: Results of the BMT CTN 1801 study

Meeting Abstract

Kean, L.; Siegel, S. J.; Schmalz, J. T.; Bien, S. A.; Scheffey, D.; Sanders, C.; Robins, H.; Applegate, K.; Bar, M.; Chhabra, S.; more...
Blood (2023)

Fulltext@MSK | Save

Predictors of cytokine release syndrome and neurotoxicity in patients with large B-cell lymphoma and their impact on survival

Meeting Abstract

Shouval, R.; Strouse, C.; Kim, S.; Oloyede, T.; Ahmed, S.; Awan, F. T.; Bachanova, V.; Badar, T.; Barba, P.; Beitinjaneh, A. M.; more...
Blood (2023)

Fulltext@MSK | Save

Real-world evidence in the United States (US) of the impact of bridging therapy prior to axicabtagene ciloleucel (axi-cel) for the treatment of relapsed or refractory large B-cell lymphoma (R/R LBCL)

Meeting Abstract

Cook, M. R.; Shouval, R.; Perales, M. A.; Bezerra, E.; Niu, A.; Dahiya, S.; Nastoupil, L. J.; Jacobson, C. A.; Budde, L. E.; Olson, A. L.; more...
Blood (2023)

Fulltext@MSK | Save

ALLO-647 for lymphodepletion in the allogeneic CAR T setting: Safety experience with ALLO-501/501A in patients (pts) with relapsed/refractory (r/r) large B-cell and follicular lymphomas

Meeting Abstract

Locke, F. L.; Munoz, J. L.; Tees, M. T.; Lekakis, L. J.; Eradat, H. A.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S. A.; Shouse, G. P.; more...
Blood (2023)

Fulltext@MSK | Save

Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk acute myeloid leukemia (AML) and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) maintenance post-hematopoietic cell transplant (HCT)

Meeting Abstract

DiPersio, J.; Cooper, B. W.; Suh, H. C.; Koura, D.; Bernard, L.; Shah, N. N.; Walter, R. B.; Perales, M. A.; Mapara, M.; Tamari, R.; more...
Blood (2023)

Fulltext@MSK | Save